Legacy Private Trust Co. Sells 1,255 Shares of McKesson Corporation $MCK

Legacy Private Trust Co. decreased its holdings in shares of McKesson Corporation (NYSE:MCK) by 9.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,745 shares of the company’s stock after selling 1,255 shares during the quarter. Legacy Private Trust Co.’s holdings in McKesson were worth $9,634,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MCK. J.W. Cole Advisors Inc. boosted its holdings in shares of McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after buying an additional 1,329 shares during the period. Private Wealth Partners LLC grew its stake in McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after buying an additional 1,682 shares during the last quarter. AlphaQuest LLC raised its holdings in McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after acquiring an additional 843 shares during the period. CW Advisors LLC lifted its position in McKesson by 282.5% during the second quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after acquiring an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of McKesson by 12.4% during the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after acquiring an additional 36,451 shares during the period. 85.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president owned 2,268 shares in the company, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,868 shares of company stock valued at $3,743,820 in the last ninety days. Insiders own 0.08% of the company’s stock.

McKesson Trading Down 1.2%

NYSE MCK opened at $888.28 on Friday. The company has a market cap of $108.81 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 1.43 and a beta of 0.38. The company has a 50 day moving average of $903.68 and a 200-day moving average of $833.49. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter in the prior year, the business posted $8.03 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities research analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is 9.43%.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Barclays upped their target price on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Morgan Stanley restated an “overweight” rating and issued a $966.00 price target on shares of McKesson in a research note on Thursday, January 29th. Leerink Partners reaffirmed an “outperform” rating and issued a $1,085.00 price objective on shares of McKesson in a report on Thursday, March 5th. Wells Fargo & Company increased their price objective on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $960.93.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.